Fraunhofer Institute for Toxicology and Experimental Medicine

Fraunhofer researchers have succeeded in producing a bioresorbable membrane that is neither cytotoxic nor genotoxic.

Project iGUARD receives 1.5 million euros follow-up funding for rapid therapies against viral diseases.

Precise therapeutics testing - preventing animal testing.

Through the establishment of a Division of Cardiovascular Research in 2021, the long-standing expertise in lung research is experiencing a synergetic further development of high clinical relevance. 

The Fraunhofer ITEM Division of Personalized Tumor Therapy in Regensburg is aimed at understanding a patient’s individual condition, establishing appropriate diagnostics and optimizing therapies.

Based on the next generation risk assessment concept, Fraunhofer ITEM develops new assessment strategies to provide predictive models for assessing the safety of compounds, active pharmaceutical ingredients and drugs.

The development, formulation and mode of delivery of anti-infective agents, for example for inhaled administration as drug aerosols, are research topics of current interest at the institute.